{
  "docId": "019de074-1cfe-7508-8ae3-4ba4db03f42e",
  "docSlug": "98d74dc525a4b13d13a1ee51c3af4583",
  "documentTitle": "Kymera | Results Presentation Deck | 63 slides",
  "authorId": "kymera",
  "authorName": "Kymera",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 27,
  "pageCount": 63,
  "prevPage": 26,
  "nextPage": 28,
  "slideType": "appendix_methodology",
  "function": "present_framework",
  "density": "overcrowded",
  "nDataPoints": 14,
  "notes": "The slide outlines a multi-part clinical trial (Parts A, B, and C) with specific dosing, randomization, and outcome metrics.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-1cfe-7508-8ae3-4ba4db03f42e/27",
  "deckHref": "/decks/019de074-1cfe-7508-8ae3-4ba4db03f42e",
  "deckJsonHref": "/decks/019de074-1cfe-7508-8ae3-4ba4db03f42e.json",
  "deckAnchorHref": "/decks/019de074-1cfe-7508-8ae3-4ba4db03f42e#slide-27",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.4,
        "x": 0.55,
        "y": 0.0055
      },
      "kind": "list",
      "text": "Primary: Safety & tolerability; Secondary/Exploratory: Pharmacokinetic measures, IRAK4 knockdown, inflammatory biomarkers, Ex vivo response, Clinical endpoints",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ae797386-26e9-4588-9ba9-d4a7bec1d694",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.23,
        "y": 0.0065
      },
      "kind": "paragraph",
      "text": "Part C: 1 cohort, 21 HS and AD patients, 75 mg (fed state), Open-label, 28x daily doses",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0660e57f-8ed1-4031-8b94-2e94ca3c8134",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.22,
        "x": 0.245,
        "y": 0.35
      },
      "kind": "paragraph",
      "text": "5 MAD cohorts: 12 subjects per cohort (9:3 randomization); 60 adult healthy subjects dosed; 14x daily doses (25-200 mg, MAD 1-4); 5x twice-weekly doses (200 mg, MAD5)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6e64d128-eee4-42eb-a4b6-2c3cf0b317c1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.52,
        "y": 0.00115
      },
      "kind": "paragraph",
      "text": "Summary of Key Findings in MAD: IRAK4 degradation of 80-90% in PBMC; Dose-dependent IRAK4 degradation in skin of >50%; Generally well tolerated; Non-adverse QTcF prolongation",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "874d67af-9866-4f28-ac92-f6ad24e7f80b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.22,
        "x": 0.245,
        "y": 0.0011799999999999998
      },
      "kind": "paragraph",
      "text": "9 SAD cohorts: 8 subjects per cohort (6:2 randomization) including 2 food-effect cohorts; 72 adult healthy subjects dosed; Single dose (25-1600 mg)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b5dcc0a1-627e-4741-8bb4-4bdffe249981",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.038,
        "w": 0.384,
        "x": 0.308,
        "y": 0.025
      },
      "kind": "title",
      "text": "KT-474 Phase 1 Trial Design",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c25341d3-5412-4fe9-88ad-103a3b8955ca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.95,
        "x": 0.025,
        "y": 0.075
      },
      "kind": "title",
      "text": "Double-blind, Placebo-controlled SAD and MAD in Adult HV; Open Label Patient Cohort in HS & AD Patients",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "65086042-2f37-4b72-b3dd-41be4f0c29d9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 40,
      "from": 16,
      "beatId": "809e9a0f-9d50-40ba-9803-20ed3da54bae",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Clinical data and pipeline updates for KT-333, KT-413, and KT-474",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}